MPC Therapeutics develops a class of compounds with applications in immunotherapy and metabolic diseases.
MPC Therapeutics has raised $113K in total funding. The most recent round was Debt Financing. The last funding was announced in November 2023.
MPC Therapeutics's investors include Innosuisse, Plutus Investment Group, FONGIT Innovation Fund, KICK Ventures, Eclosion SA.
MPC Therapeutics is headquartered in Plan-les-ouates, Switzerland.
MPC Therapeutics develops a class of compounds with applications in immunotherapy and metabolic diseases.
MPC Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MPC Therapeutics — Funding & Investors." VCBacked, November 16, 2023, https://www.vcbacked.co/company/mpc-therapeutics. Accessed November 15, 2026.
VCBacked. (2023). MPC Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/mpc-therapeutics
{{cite web |title=MPC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mpc-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at MPC Therapeutics? Request a listing update